PMID- 26466333
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20220311
IS  - 1538-4683 (Electronic)
IS  - 1061-5377 (Linking)
VI  - 24
IP  - 1
DP  - 2016 Jan-Feb
TI  - Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.
PG  - 41-7
LID - 10.1097/CRD.0000000000000093 [doi]
AB  - Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the 
      first in a new class of drugs that combines neprilysin inhibition with 
      angiotensin II receptor antagonism, the combination of which acts to increase 
      endogenous natriuretic peptides while inhibiting the 
      renin-angiotensin-aldosterone system. Sacubitril/valsartan has been studied in 
      the treatment of hypertension, heart failure with reduced ejection fraction 
      (HFrEF), and heart failure with preserved ejection fraction (HFpEF) and has 
      demonstrated clinical efficacy in blood pressure reduction in hypertensive 
      patients with and without HFpEF and a reduction in hospitalizations and mortality 
      for patients with HFrEF. Research to evaluate clinical outcomes in HFpEF is 
      ongoing. Sacubitril/valsartan is approved to reduce hospitalization and risk of 
      cardiovascular death for patients with HFrEF in New York Heart Association (NYHA) 
      functional class II-IV. The product is as well tolerated as an 
      angiotensin-converting enzyme inhibitor, with the most common side effect being 
      hypotension. Expectedly, it is much more costly than generic 
      angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, 
      which will be a factor in determining how widespread the use of this agent will 
      be. In summary, although the number of published studies evaluating its use is 
      limited, sacubitril/valsartan represents a promising new treatment option for 
      patients with HFrEF. Ongoing studies will continue to refine the role of this 
      agent in clinical practice.
FAU - Sible, Alexandra M
AU  - Sible AM
AD  - From the *Department of Pharmacy, University of New Mexico, Albuquerque, NM; and 
      daggerDepartment of Medicine, North Shore-Long Island Jewish Health System, Great 
      Neck, NY.
FAU - Nawarskas, James J
AU  - Nawarskas JJ
FAU - Alajajian, David
AU  - Alajajian D
FAU - Anderson, Joe R
AU  - Anderson JR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiol Rev
JT  - Cardiology in review
JID - 9304686
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Natriuretic Peptides)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aminobutyrates/pharmacology/*therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/pharmacology/*therapeutic use
MH  - Biphenyl Compounds
MH  - Drug Combinations
MH  - Enzyme Inhibitors/pharmacology/*therapeutic use
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Natriuretic Peptides/metabolism
MH  - Neprilysin/*antagonists & inhibitors/metabolism
MH  - Renin-Angiotensin System/drug effects
MH  - Stroke Volume
MH  - Tetrazoles/pharmacology/*therapeutic use
MH  - Valsartan
EDAT- 2015/10/16 06:00
MHDA- 2016/09/16 06:00
CRDT- 2015/10/15 06:00
PHST- 2015/10/15 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
AID - 10.1097/CRD.0000000000000093 [doi]
PST - ppublish
SO  - Cardiol Rev. 2016 Jan-Feb;24(1):41-7. doi: 10.1097/CRD.0000000000000093.